Artwork

Innhold levert av Oncolgy Times and Audio Medica. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Oncolgy Times and Audio Medica eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Oncology Times Broadcast News with the Audio Journal of Oncology - November 2008

20:17
 
Del
 

Manage episode 153458764 series 1090654
Innhold levert av Oncolgy Times and Audio Medica. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Oncolgy Times and Audio Medica eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Oncology Times Broadcast News with the Audio Journal of Oncology Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Gordon McVie, European Institute of Oncology, Milan Pat Price, Christie Hospital, Manchester Gianni Bonadonna, Istituto Nazionale Tumori, Milan REPORTING FROM: National Cancer Research Institute Cancer Conference, October 5-8, 2008, Birmingham, England American Society of Clinical Oncology Annual Meeting, May 30-June 3, 2008, Chicago, Illinois, Perspectives In Lung Cancer 9th European Congress, March 14-15, Torino, Italy Sarah Maxwell and Peter Goodwin report on evidence that combining monoclonal antibodies with chemotherapy can extend life among patients with advanced non-small-cell lung cancer. Robert Pirker from the Medical University of Vienna tells Sarah Maxwell about his group's findings in the FLEX study using the epidermal growth factor receptor (EGF-R) inhibitor cetuximab; Christian Manegold from Heidelberg Universit, Manheim gives Peter Goodwin data on the vascular endothelial growth factor (VEGF-R) bevacizumab; while Giorgio Scagliotti from Torino University, Nick Thatcher from the Christie Hospital, Manchester and Howard Sandler from the University of Michigan, Ann Arbor discuss the clinical implications of these approaches to using molecular targeting to improve outcomes in advanced non-small-cell lung cancer. Michel Coleman from the London School of Hygiene and Tropical Medicine tells Peter Goodwin about the findings of the CONCORD study looking at international differences between survival rates for breast, prostate and colorectal cancers.
  continue reading

19 episoder

Artwork
iconDel
 
Manage episode 153458764 series 1090654
Innhold levert av Oncolgy Times and Audio Medica. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Oncolgy Times and Audio Medica eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Oncology Times Broadcast News with the Audio Journal of Oncology Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Gordon McVie, European Institute of Oncology, Milan Pat Price, Christie Hospital, Manchester Gianni Bonadonna, Istituto Nazionale Tumori, Milan REPORTING FROM: National Cancer Research Institute Cancer Conference, October 5-8, 2008, Birmingham, England American Society of Clinical Oncology Annual Meeting, May 30-June 3, 2008, Chicago, Illinois, Perspectives In Lung Cancer 9th European Congress, March 14-15, Torino, Italy Sarah Maxwell and Peter Goodwin report on evidence that combining monoclonal antibodies with chemotherapy can extend life among patients with advanced non-small-cell lung cancer. Robert Pirker from the Medical University of Vienna tells Sarah Maxwell about his group's findings in the FLEX study using the epidermal growth factor receptor (EGF-R) inhibitor cetuximab; Christian Manegold from Heidelberg Universit, Manheim gives Peter Goodwin data on the vascular endothelial growth factor (VEGF-R) bevacizumab; while Giorgio Scagliotti from Torino University, Nick Thatcher from the Christie Hospital, Manchester and Howard Sandler from the University of Michigan, Ann Arbor discuss the clinical implications of these approaches to using molecular targeting to improve outcomes in advanced non-small-cell lung cancer. Michel Coleman from the London School of Hygiene and Tropical Medicine tells Peter Goodwin about the findings of the CONCORD study looking at international differences between survival rates for breast, prostate and colorectal cancers.
  continue reading

19 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett